AbstractBackgroundThe TCGA molecular groups of endometrial carcinoma are “POLE‐mutated” (POLEmut), “microsatellite‐instable/mismatch repair‐deficient” (MSI/MMRd), “TP53‐mutated/p53‐abnormal” (TP53mut/p53abn), and “no specific molecular profile” (NSMP).ObjectivePrognostic assessment of the TCGA groups in uterine carcinosarcoma (UCS).Search strategySystematic review from January 2000 to January 2021.Selection criteriaStudies assessing the TCGA groups in UCS.Data collection and analysisProgression‐free survival (PFS) and overall survival (OS) were assessed by Kaplan–Meier and Cox analyses (reference: TP53mut/p53abn group) and compared with endometrioid and serous carcinomas (original TCGA cohort), with a significant P < 0.050.Main resultsFive studies with 263 UCS were included. Compared with TP53mut/p53abn UCS, MSI/MMRd UCS showed significantly better PFS (P < 0.001) but similar OS (P = 0.788), whereas NSMP UCS showed similar PFS (P = 0.936) and OS (P = 0.240). Compared with their endometrioid/serous counterparts, NSMP and TP53mut/p53abn UCS showed significantly worse PFS (P < 0.001 and P = 0.004) and OS (P < 0.001 and P < 0.001), while MSI/MMRd UCS showed similar PFS (P = 0.595) but significantly worse OS (P < 0.001). The POLEmut group showed neither recurrences nor deaths in both the UCS and the endometrioid/serous carcinoma cohorts.ConclusionPOLEmut UCS show excellent prognosis, whereas TP53mut/p53abn and NSMP UCS show a prognosis even worse than that of TP53mut/p53abn endometrioid/serous carcinomas. The prognosis of MSI/MMRd UCS remains to be defined.